Valneva vaccineDate: 23 October 2021 Tags: Miscellaneous
French vaccine manufacturer Valneva SE has released its data from Phase 3 trial of its inactivated Covid-19 vaccine candidate.
The vaccine has been named VLA2001 and it is found to be as effective as Oxford/AstraZeneca vaccine.
VLA2001 is an adjuvanted and inactivated vaccine that delivers the whole Sars-CoV-2 virus in an inactivated form.
The virus is killed using heat, radiation or chemicals. The inactivated form is unable to harm the body but can generate immune response.
Using inactivated form of virus to get an immune response is commonly used in Polio and flu vaccines. The Covaxin manufactured by Bharat Biotech is also this category.
Significance of Valneva
The vaccine can be stored in a common refrigerator, making it easier to transport than the existing ones which require low temperatures.
The phase-3 trial was known as ‘Cov-Compare’ and involved participants above the age of 18 years. They were studied in two trial groups.
In adults aged 30 or more, the vaccine was able to generate high neutralizing anti-bodies than Oxford/AstraZeneca vaccine. A broad T-cell response was generated.
The Valneva receiving group showed low levels of adverse effects compared to the group given the Oxford/AstraZeneca vaccine.